{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:39:52Z","timestamp":1761129592008},"reference-count":23,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2019,1,31]]},"DOI":"10.7883\/yoken.jjid.2018.314","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T18:27:11Z","timestamp":1540924031000},"page":"49-52","source":"Crossref","is-referenced-by-count":10,"title":["Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV)"],"prefix":"10.7883","volume":"72","author":[{"given":"Tetsuo","family":"Nakayama","sequence":"first","affiliation":[{"name":"Kitasato Institute for Life Sciences, Laboratory of Viral Infection"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Suga","sequence":"additional","affiliation":[{"name":"National Mie Hospital, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Okada","sequence":"additional","affiliation":[{"name":"Fukuoka Nursing College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Okabe","sequence":"additional","affiliation":[{"name":"Kawasaki City Institute for Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1.                Takatsu T, Tagaya I, Hirayama M. Poliomyelitis in Japan during the period 1962\u201368 after the introduction of mass vaccination with Sabin vaccine. Bull World Health Organ. 1973;49:129-37."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2.                Shimizu H. Poliovirus vaccine. Uirusu. 2012;62:57-65. Japanese.","DOI":"10.2222\/jsv.62.57"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3.                Miyamura T. Ten years after polio eradication from the WPRO region: current status and future problems. Vaccine. 2012;30:1406-8.","DOI":"10.1016\/j.vaccine.2011.12.050"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4.                Nakayama T. Vaccine chronicle in Japan. J Infect Chemother. 2013;19:787-98.","DOI":"10.1007\/s10156-013-0641-6"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5.                Zepp F, Knuf M, Heininger U, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugated vaccine, for primary immunization of infants. Vaccine. 2004;22:2226-33.","DOI":"10.1016\/j.vaccine.2003.11.044"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6.                Capiau C, Poolman J, Hoet B, et al. Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned. Vaccine. 2003;21:2273-87.","DOI":"10.1016\/S0264-410X(03)00107-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7.                de Melker HE, Schellekens JF, Neppelenbroek SE, et al. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6:348-57.","DOI":"10.3201\/eid0604.000404"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hellenbrand W, Beier D, Jensen E, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis. 2009;9-22.","DOI":"10.1186\/1471-2334-9-22"},{"key":"9","unstructured":"9.                Centers for Diseases Control and Prevention. Pertussis epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61:517-22."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10.                McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: A meta- analysis. Pediatrics. 2015;135:331-43.","DOI":"10.1542\/peds.2014-1729"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11.                Miyaji Y, Otsuka N, Toyoizumi-Ajisaka H, et al. Genetic analysis of Bordetella pertussis isolates from the 2008\u20132010 pertussis epidemic in Japan. PLoS One. 2013;8:e77165.","DOI":"10.1371\/journal.pone.0077165"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12.                Hara M, Fukuoka M, Tashiro K, et al. Pertussis outbreak in university students and evaluation of acellular pertussis vaccine effectiveness in Japan. BMC Infect Dis. 2015;15:45.","DOI":"10.1186\/s12879-015-0777-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13.                Oguchi K, Miyata A, Kazuyama Y, et al. Detection of antibodies against fimbria type 3 (Fim3) is useful diagnostic assay for pertussis. J Infect Chemother. 2015;21:639-46.","DOI":"10.1016\/j.jiac.2015.05.006"},{"key":"14","unstructured":"14.                Nakayama T, Yamauchi H, Esteban O, et al. The Immunogenicity and safety of a new quadruple combination vaccine, including undiluted IPV (Salk vaccine). J Jpn Pediatr Society. 2015;119(4):669-79."},{"key":"15","unstructured":"15. World Health Organization (WHO). Guidelines for WHO\/EPI collaborative studies on poliomyelitis: Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO\/EPI\/GEN\/93.9. Geneva: WHO; 1993."},{"key":"16","doi-asserted-by":"publisher","unstructured":"16.                Gustafsson L, Hessel L, Storsaeter J, et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006;118:978-84.","DOI":"10.1542\/peds.2005-2746"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17.                Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis. 2011;11:557-70.","DOI":"10.1016\/S1473-3099(11)70007-X"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18.                Aase A, Herstad TK, J\u00f8rgensen SB, et al. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7\u20138 years of age. Vaccine. 2014;32:5931-6.","DOI":"10.1016\/j.vaccine.2014.08.069"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19.                Yasui Y, Mitsui T, Nishimura T, et al. School-age children and adolescents suspected of having been to be infected with pertussis in Japan. Vaccine. 2018;36:2910-5.","DOI":"10.1016\/j.vaccine.2018.01.048"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20.                Okada K, Miyazaki C, Kino Y, et al. Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV). J Infect Dis. 2013;208:275-83.","DOI":"10.1093\/infdis\/jit155"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21.                Vidor E. Poliovirus vaccine-inactivated. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM,  editors. Plotkin\u2019s Vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p.841-64.","DOI":"10.1016\/B978-0-323-35761-6.00047-X"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22.                Esposito S, Tagliabue C, Bosis S, et al. Hexavalent vaccines for immunization in paediatric age. Clin Microbiol Infect. 2014;20 Suppl 5:76-85.","DOI":"10.1111\/1469-0691.12444"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23.                Salk D, van Wezel AL, Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet. 1984;2(8415):1317-21.","DOI":"10.1016\/S0140-6736(84)90830-4"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/72\/1\/72_JJID.2018.314\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T21:39:11Z","timestamp":1548538751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/72\/1\/72_JJID.2018.314\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2018.314","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]}}}